TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01467856

Intervention type: PROCEDURE
Intervention: PAP Device Procedure
Description: Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP \> 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic.
Study: NCT04089085

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STRONGer Together
Description: STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
Study: NCT02496754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH-a
Description: In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
Study: NCT04338022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (match to Teriflunomide)
Description: Placebo match to Teriflunomide once daily in DBTP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Teriflunomide once daily in DBTP.
Study: NCT03005834

Intervention type: OTHER
Intervention: incidence of cancers
Description: With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.

Intervention type: OTHER
Intervention: incidence of cancers
Description: With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
Study: NCT02507063

Intervention type: PROCEDURE
Intervention: ultrasound
Description: Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
Study: NCT05021276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
Study: NCT00521508

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gene transcription and cytometry
Description: samply of 30 ml of blood
Study: NCT04338022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (match to Evobrutinib)
Description: Placebo match to Evobrutinib BID in DBTP.
Study: NCT01477216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods
Study: NCT00521508

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gene transcription and cytometry
Description: samply of 30 ml of blood

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gene transcription and cytometry
Description: samply of 30 ml of blood
Study: NCT01477216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods
Study: NCT00664196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
Study: NCT02664415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg; administered IV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VRC01
Description: Sodium Chloride for Injection 0.9%, USP; administered IV
Study: NCT03749707

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV analysis
Description: HPV analysis of SLNs
Study: NCT01969760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families DC Program
Description: A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
Study: NCT04019821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study: NCT04484090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertica RF device
Description: The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
Study: NCT03611387

Intervention type: DEVICE
Intervention: CASIA 2 OCT
Description: Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods

Intervention type: DEVICE
Intervention: CASIA 2 OCT
Description: Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods

Intervention type: DEVICE
Intervention: CASIA 2 OCT
Description: Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
Study: NCT02509286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m² (24 hours), d1 every two weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant radiation
Description: 41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
Study: NCT02247687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protease inhibitor
Description: Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isentress® (raltegravir)
Description: • Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling arm
Description: No change of antiretroviral treatment but only counseling
Study: NCT00643305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Building with Motivational Interviewing
Description: Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills Building
Description: Participants are provided with information and training in skills critical for reducing HIV risk.
Study: NCT03720548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372993
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372993
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study: NCT01071876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 1 capsule in the morning before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule in the morning before breakfast
Study: NCT01559116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: low dose + one dose only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olodaterol
Description: one dose only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: low dose + one dose only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tiotropium+olodaterol FDC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study: NCT02496754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH-a
Description: In control group, patients use short term GnRH-a. Patients' serum or follicle fluid will be collected if needed.
Study: NCT01559116

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study: NCT04019821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study: NCT04002089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: bupivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: bupivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: bupivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.3%, 13.3 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.3%, 13.3 mg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1.3%, 13.3 mg/mL
Study: NCT01775046

Intervention type: DEVICE
Intervention: DTA patients (Valiant)
Description: Valiant Thoracic Stent Graft Implantation
Study: NCT03110679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of autologous bone marrow concentrate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of hyaluronic acid.
Study: NCT01559116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study: NCT00694044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 21 days
Study: NCT04837456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calorie restricted diet and exercise intervention
Description: the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: libitum diet and waiting list control group
Description: libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early arthroscopic partial menisectomy group
Description: Early APM group participants received APM with syndrome within 3 to 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed APM group recruit participants with symptoms lasting for more than 6 months
Description: delayed APM group recruit participants with symptoms lasting for more than 6 months
Study: NCT04292691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40ml of Ropivacaine 0.5% Injectable Solution
Description: already outlined in the arm/group description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40ml of Ringer's Lactate
Description: already outlined in the arm/group description
Study: NCT01009385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical epidural steroid injection
Description: * After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical epidural steroid injection
Description: * After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination
Study: NCT03031951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Group
Description: The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from \~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
Study: NCT03697226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968
Description: Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
Study: NCT00838162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 75 mg twice daily
Description: TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 150 mg twice daily
Description: TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
Study: NCT01009385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural pressure measurement
Description: * The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural pressure measurement
Description: * The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system.
Study: NCT06260176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to healthy labels only
Description: Green labels only for beverages and foods scored as healthy
Study: NCT00838162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg twice daily
Description: TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg once daily
Description: TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice daily
Description: Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice daily
Description: Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice daily
Description: Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg once daily
Description: Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
Study: NCT05696548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered at a dose of 24mg as oral dose, one a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
Study: NCT06260176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to healthiness information
Description: All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
Study: NCT03234309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study: NCT06260176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to physical activity equivalents
Description: All beverages and foods labeled with physical activity required to burn their calories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to sweetened beverage tax messaging
Description: Message reminding consumers to make healthier choices
Study: NCT02864745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation-assisted cycle ergometry
Description: Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard rehabilitation
Description: This group will receive standard rehabilitation, which will be monitored, but not protocolised.
Study: NCT02532868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0457
Study: NCT04590937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRESTOR®
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenoxin®
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetfoLiquid GeriaSan®
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasix®
Description: Oral solution